Zynex, Inc.

Good afternoon, ladies and gentlemen, and welcome to the Zynex first quarter 2022 earnings conference call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to Louisa Smith from the Gilmartin Group. Please go ahead.

Thank you, Joe, and good afternoon, everyone. Earlier today, Zynex released financial results for the first quarter 2022. A copy of the press release is available on the company's website. Joining me on today's call are Thomas Sangard, Chairman, President, and Chief Executive Officer, Dan Moorhead, Chief Financial Officer, Anna Lukczak, Chief Operating Officer, and Donald Gregg, Vice President of Zynex Monitoring Solutions. Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including without limitation, the company's 2021 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources, or operating performance. With that, I'll now turn the call over to Thomas.

Thank you, Louisa, and good afternoon, everyone. Thank you for joining us today for the first quarter 2022 earnings call. We had another solid quarter of growth and profitability. Our total revenue was $31.1 million for the quarter, an increase of 29% year over year, all generated in our pain management division. Our earnings for the quarter were $0.03 per share, up from $0.02 per share loss a year ago, and adjusted EBITDA was $3.1 million. Our order growth continues, with the month of March recording the highest number of orders in the company's history. Several months ago, we announced a $10 million share buyback program to signal our confidence in the long-term success and growth of Sinex. We have always been committed to delivering shareholder value, and we believe purchasing shares at these prices creates value for our long-term shareholders. The first quarter performance was a reflection of a company's capacity to execute operationally and strategically, and we remain on track for our 2022 annual revenue guidance of $150 to $170 million. During the first quarter, the monitoring division completed the integration of Kestrel Labs and its laser-based pulse oximetry products. In the quarters, In the first quarter, we also added a significant amount of engineering and clinical research personnel to the division and are gearing up for manufacturing and sales of the CM1600, our second-generation blood and fluid monitor. We anticipate these things to take place during the third quarter of the year, pending FDA clearance, obviously. As our audience may recall earlier, The first-generation product, CM1500, is already cleared by the FDA. I will now turn the call over to Anna Luxorg, our Chief Operating Officer.